Indianapolis, Indiana 46256

  • Chronic Migraine

Purpose:

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine


Criteria:

Inclusion Criteria: - Eligible participants who completed Visit 7, and Visit 8 if applicable, of Study 3101-303-002 or Study 3101-304-002 without significant protocol deviations and who did not experience an Adverse Event that may indicate an unacceptable safety risk. Exclusion Criteria: - Participants requiring any medication, diet, or nonpharmacological treatment on the list of prohibited concomitant medications or treatments that cannot be discontinued or switched to an allowable alternative. - Participants with an ECG indicating clinically significant abnormalities at Visit 1. - Participants with hypertension at Visit 1. - Participants with a significant risk of self-harm, or of harm to others; participants who report suicidal ideation with intent, with or without a plan, since the last visit, must be excluded. - Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.


NCT ID:

NCT04686136


Primary Contact:

Study Director
Joel Trugman
Allergan

Clinical Trials Registry Team
Phone: 877-277-8566
Email: IR-CTRegistration@Allergan.com


Backup Contact:

N/A


Location Contact:

Indianapolis, Indiana 46256
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 01, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.